Despite being FDA-approved for COVID-19, the clinical efficacy of remdesivir (Veklury) remains contentious. We previously pointed out pharmacokinetic, pharmacodynamic and toxicology reasons for why its parent nucleoside GS-441524, is better suited for COVID-19 treatment. Here, we assess the oral bioavailability of GS-441524 in beagle dogs and show that plasma concentrations ~24-fold higher than the EC against SARS-CoV-2 are easily and safely sustained. These data support translation of GS-441524 as an oral agent for COVID-19.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183013 | PMC |
| http://dx.doi.org/10.1101/2021.02.04.429674 | DOI Listing |
Publication Analysis
Top Keywords
pharmacokinetics orally
4
orally administered
4
gs-441524
4
administered gs-441524
4
gs-441524 dogs
4
dogs despite
4
despite fda-approved
4
fda-approved covid-19
4
covid-19 clinical
4
clinical efficacy
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!